Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 September 2021 | Story Leonie Bolleurs | Photo Sonia Small (Kaleidoscope Studios)
Dr Molapo Qhobela, the newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact, will be speaking at the International Summit on the Sustainable Development Goals (SDGs) in Africa 2021.

Dr Molapo Qhobela, the newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact at the University of the Free State (UFS), will be speaking at the three-day International Summit on the Sustainable Development Goals (SDGs) in Africa 2021. The summit will take place as follows:

Date: 13-15 September 2021 
Platform: A virtual gathering (register for the upcoming virtual summit)

Together with a wide array of thought leaders, including specialists, senior researchers, CEOs/directors, and the top structures of international organisations, he will address and engage with an audience of academics, practitioners, government authorities, representatives from civil society, and donors and sponsors from across the globe on the topic Partnerships for impact in Africa (session on 15 September from 12:30 to 14:00).

According to the host of the event, the University of Cape Town, the key aim of the International Summit on the SDGs in Africa is to mobilise collaborative efforts that will accelerate African-led activities in support of achieving the African Union's Agenda 2063 and the United Nations Sustainable Development Goals (SDGs) – a shared blueprint for working towards global peace and prosperity by 2030. The summit is also designed to identify concrete opportunities for research collaboration that will accelerate the achievement of the SDGs and Agenda 2063.

The talks, panel discussions, workshops, and breakout sessions will revolve around clear steps for implementation.

For more information, visit: http://www.sdgsafricasummit.uct.ac.za/

Background of Dr Molapo Qhobela

Dr Qhobela’s leadership and strategic direction have been sought by several large and complex organisations during his career. He is the immediate former Chief Executive Officer (CEO) of the National Research Foundation, and also the former Chair of the Global Research Council as well as the Agricultural Research Council. He is currently the Chairperson of the Tertiary Education and Research Network of South Africa. Dr Qhobela holds a PhD in Plant Pathology from the Kansas State University in the United States of America.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept